SYM	Name
	SPAC/IPO
	LOI
	Vereinbarung
	Wahl
	Fusion
	IPO
	Abwicklung

HSPT Clarifies Share Redemption for SL BIO Merger Vote

7/10Feb 03, 2026

Biotechnology

Special Meeting of Shareholders

Merger:

Jun 15, 2026

SL Science Holding Ltd (SLBT)Horizon Space Acquisition II Corp.

🔒 Login for Watchlists

Industry:

BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

slbtgroup.com ir.slbtgroup.com

Show Chart?

Load external content from TradingView!

*You can change or withdraw your consent at any time in the footer under Cookies.

Horizon Space Acquisition II Corp. Clarifies Share Redemption Process for Upcoming Shareholder Meetings

Feb 03, 2026 3:13 PM ET

New York, NY, USA - Horizon Space Acquisition II Corp. (NASDAQ: HSPT) today clarified the redemption process for its public shareholders in connection with two crucial upcoming extraordinary general meetings.

These meetings include the Business Combination Meeting, scheduled for February 12, 2026, to vote on the proposed business combination with SL BIO Ltd. (SL Bio), and the Extension Meeting, set for February 13, 2026, to consider amendments extending the deadline for HSPT to complete its initial business combination.

... Read on — Members only

About SL Science Holding Ltd

SL Bio is a biomedical company focused on developing innovative cellular and gene therapies for cancer treatment and regenerative medicine. Leveraging proprietary technologies and strategic partnerships, the company is advancing next-generation immunotherapies and exosome-based products for both medical and consumer applications. SL Bio’s approach combines scientific expertise with a commitment to improving patient outcomes and addressing unmet needs in healthcare. SL Bio also offers ISO-certified, dermatologically tested cow milk-derived exosome-based products and plant extract products for skin and hair care, with commercial distribution in Asia.

View Company Details

More SLBT News

6/10 Jul 10, 2026

SL Science Submits FDA Orphan Drug Request for Glioblastoma

SL Science Holding Limited submits Orphan Drug Designation request to the FDA for its GDT cell therapy targeting…

Business Update Biotechnology SLBT

Top Free

8/10 Jun 15, 2026

SL Bio Lists on Nasdaq Following Merger with Horizon Space

SL Bio completes its business combination with Horizon Space Acquisition II Corp, with shares beginning to trade on…

Merger / DESPAC Biotechnology SLBT

3/10 Jan 30, 2026

HSPT Postpones Shareholder Meeting, Extends Redemption Deadline

Horizon Space Acquisition II Corp. (HSPT) postpones its extraordinary general meeting to February 12, 2026, and extends the…

Extension Biotechnology SLBT

Top

8/10 May 12, 2025

Horizon SPAC II and SL Bio Announce Nasdaq Business Combination

Horizon Space Acquisition II Corp. and SL Bio Ltd. announce a definitive business combination. SL Bio, a clinical-stage…

Definitive Agreement Biotechnology SLBT

5/10 Feb 04, 2025

Horizon Space Acquisition II Corp. Units to Trade Separately

Horizon Space Acquisition II Corp. (HSPT) announced that its units will begin trading separately as shares and rights…

Unit Split Biotechnology SLBT

7/10 Nov 18, 2024

Horizon Space Acquisition II Corp. $60M IPO Priced

Horizon Space Acquisition II Corp. (Nasdaq: HSPTU) announces pricing of its $60 million initial public offering, comprising 6M…

Initial Public Offering / IPO SPAC Biotechnology SLBT

Biotechnology

Free

7/10 Jul 30, 2026

Evommune Starts Phase 2b Trial for Migraine Drug EVO756

Evommune, Inc. has initiated a Phase 2b clinical trial for its MRGPRX2 inhibitor, EVO756, targeting migraine prophylaxis. Top-line…

Business Update Biotechnology EVMN

Top Free

8/10 Jul 27, 2026

Oak Hill Bio to Go Public via RACC SPAC Merger

Oak Hill Bio and Research Alliance Corporation III announce a business combination to advance rugonersen for Angelman syndrome,…

Definitive Agreement Biotechnology RACC

6/10 Jul 10, 2026

SL Science Submits FDA Orphan Drug Request for Glioblastoma

SL Science Holding Limited submits Orphan Drug Designation request to the FDA for its GDT cell therapy targeting…

Business Update Biotechnology SLBT

Free

7/10 Jun 24, 2026

LakeShore Biopharma Completes Going Private Merger

LakeShore Biopharma (LSBCF) announces the completion of its going private transaction. Shareholders to receive 0.066 USD per share.

Delisting Biotechnology LSB

Top

8/10 Jun 23, 2026

Agomab Reveals NOV-ERA Phase 2b Design for Crohn's Disease

Agomab Therapeutics announces FDA-aligned Phase 2b study design for ontunisertib in Fibrostenosing Crohn's Disease. Trial expected to begin…

Business Update Biotechnology AGMB

Free

7/10 Jun 18, 2026

NeOnc Technologies Gets UAE IND Approval for NEO212

NeOnc Technologies receives IND clearance in Abu Dhabi for its brain cancer drug NEO212, marking a step toward…

Business Update Biotechnology NTHI

Special Meeting of Shareholders

4/10 Apr 06, 2026

Willow Lane Reschedules Shareholder Meeting to April 30

Willow Lane Acquisition Corp (WLAC) has rescheduled its extraordinary general meeting to April 30, 2026, pending the effectiveness…

Special Meeting of Shareholders Internet Service BRUN

4/10 Mar 19, 2026

Vine Hill Capital: EGM Location Change for Business Combo Vote

Vine Hill Capital Investment Corp. (VCIC) announced a change in the physical location for its Extraordinary General Meeting…

Special Meeting of Shareholders Crypto / Blockchain CSHR

Daily overview of upcoming SPAC and IPO events – from initial announcement to definitive agreement and public listing.

SPAC & IPO Calendar

Discover last week’s SPAC and IPO highlights, key trends, and market updates. Stay informed with SpacStar.

Last Week Events